Replies to post #211465 on Anavex Life Sciences Corp (AVXL)

[Investor2014]

"We believe the data presentation could include the PK data and data from the placebo-treated patients, Janney analyst Yun Zhong said in a recent note.

Doesn't make much sense to me for two reasons?

1) pharmacokinetics of placebo in itself, and
2) there was no placebo arm for the initial 6 patients PK study

Logically even this can't apply Does the placebo effect modulate drug bioavailability? Randomized cross-over studies of three drugs

Surely Zhong can't be referring to the quadruple blinded study that hasn't even completed enrollment yet.

Or maybe I have just lost my marbles.